Deutscher Platz 5a
Leipzig 04103
Germany
49 341 48792 40
https://www.vita34.de
Settore/i:
Settore:
Impiegati a tempo pieno: 775
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Jakub Julian Baran | Chairman of the Management Board & CEO | N/D | N/D | N/D |
Mr. Tomasz Franciszek Baran | VP of the Management Board & Chief Commercial Officer | N/D | N/D | N/D |
Mr. Dirk Plaga | CFO & Member of Management Board | N/D | N/D | 1965 |
Santiago Luengo | Managing Director of Secuvita | N/D | N/D | N/D |
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
L'ISS Governance QualityScore di VITA 34 AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.